Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. (CHGCF) Revenue
Annual & quarterly revenue history · segment & region breakdown
CHGCF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsChugai Pharmaceutical Co., Ltd. trailing twelve-month (TTM) revenue is $1298B, an increase of 7.55% year-over-year from $1259B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1259B | +$88.43B | +7.55% |
| 2024-12-31 | $1171B | +$59.24B | +5.33% |
| 2023-12-31 | $1111B | -$148.58B | -11.79% |
| 2022-12-31 | $1260B | +$260.19B | +26.02% |
| 2021-12-31 | $1000B | +$212.81B | +27.04% |
| 2020-12-31 | $787B | +$100.76B | +14.68% |
| 2019-12-31 | $686B | +$106.40B | +18.35% |
| 2018-12-31 | $580B | +$45.59B | +8.53% |
| 2017-12-31 | $534B | +$42.42B | +8.63% |
| 2016-12-31 | $492B | -$7.06B | -1.42% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare CHGCF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Chugai Pharmaceutical Co., Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Chugai Pharmaceutical Co., Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in JPY.
Data sourced from Chugai Pharmaceutical Co., Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CHGCF revenue · 4 questionsCHGCF's trailing twelve-month (TTM) revenue is $1298B. That is an increase of 7.55% year-over-year from $1259B in FY2025.
▸ Source: FMP · Chugai Pharmaceutical Co., Ltd. SEC filings · GAAP · Chugai Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026